FLOW CYTOMETRIC ANALYSIS OF UTERINE SARCOMA - PLOIDY AND S-PHASE RATE AS PROGNOSTIC INDICATORS

被引:21
作者
MALMSTROM, H
SCHMIDT, H
PERSSON, PG
CARSTENSEN, J
NORDENSKJOLD, B
SIMONSEN, E
机构
[1] LINKOPING UNIV HOSP,DEPT ONCOL,S-58185 LINKOPING,SWEDEN
[2] LINKOPING UNIV HOSP,DEPT PATHOL,S-58185 LINKOPING,SWEDEN
关键词
D O I
10.1016/0090-8258(92)90034-G
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Flow cytometry of various gynecological tumors has shown that aneuploid tumors and a high S-phase rate carry a prognosis worse than that of diploid tumors or tumors with a low S-phase. The aim of this study is to investigate the prognostic importance of DNA ploidy and S-phase rate in relation to mitotic count, tumor stage, tumor grade, and histology in 37 patients with uterine sarcoma stages I-IV (FIGO). Flow cytometry was performed on archival paraffin-embedded tumor tissue and the histologic specimens were reviewed by a single pathologist. Nineteen (51%) of the tumors were classified as DNA aneuploid. The S-phase fraction (SPF) was determined in 33 cases. The mean SPF (±SD) was 15.0% (±9.5%). The mean SPF was three times higher in aneuploid tumors than in diploid cases. Both the proportion of aneuploid tumors and the mean SPF were significantly higher in later stage tumors, more poorly differentiated tumors, and tumors with a higher mitotic index. No significant differences were seen between histologic types with respect to the two cytometric variables. The 5-year cancer survival rate was only 11% in aneuploid cases compared with 59% in diploid cases (log rank, P = 0.0002). There was a significantly worse prognosis in cases with a higher SPF (P = 0.0009) and in cases with a higher mitotic index (P = 0.0016). In the multivariate survival analysis using the Cox proportional hazards model, DNA ploidy showed a significant prognostic value (P = 0.046) even when adjusted for stage, grade, and mitotic index. When adjusted for stage and grade only, SPF showed significant additional prognostic value. © 1992.
引用
收藏
页码:172 / 177
页数:6
相关论文
共 40 条
[11]   CLINICAL AND BIOLOGICAL SIGNIFICANCE OF ANEUPLOIDY IN HUMAN-TUMORS [J].
FRIEDLANDER, ML ;
HEDLEY, DW ;
TAYLOR, IW .
JOURNAL OF CLINICAL PATHOLOGY, 1984, 37 (09) :961-974
[12]   NUCLEAR DNA CONTENT IN ENDOLYMPHATIC STROMAL MYOSIS [J].
GOLDFARB, S ;
RICHART, RM ;
OKAGAKI, T .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1970, 106 (04) :524-&
[13]   APPLICATION OF DNA FLOW-CYTOMETRY TO PARAFFIN-EMBEDDED ARCHIVAL MATERIAL FOR THE STUDY OF ANEUPLOIDY AND ITS CLINICAL-SIGNIFICANCE [J].
HEDLEY, DW ;
FRIEDLANDER, ML ;
TAYLOR, IW .
CYTOMETRY, 1985, 6 (04) :327-333
[14]  
IVERSEN OE, 1988, CANCER, V61, P971, DOI 10.1002/1097-0142(19880301)61:5<971::AID-CNCR2820610519>3.0.CO
[15]  
2-J
[16]   PROGNOSTIC IMPACT OF PLOIDY LEVEL IN CARCINOMA OF THE CERVIX [J].
JAKOBSEN, A .
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1984, 7 (05) :475-480
[17]  
KAHANPAA KV, 1986, OBSTET GYNECOL, V67, P417
[18]   NONPARAMETRIC-ESTIMATION FROM INCOMPLETE OBSERVATIONS [J].
KAPLAN, EL ;
MEIER, P .
JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION, 1958, 53 (282) :457-481
[19]   DNA FLOW-CYTOMETRY, CLINICAL AND MORPHOLOGICAL PARAMETERS AS PROGNOSTIC FACTORS FOR ADVANCED MALIGNANT AND BORDERLINE OVARIAN-TUMORS [J].
KUHN, W ;
KAUFMANN, M ;
FEICHTER, GE ;
RUMMEL, HH ;
SCHMID, H ;
HEBERLING, D .
GYNECOLOGIC ONCOLOGY, 1989, 33 (03) :360-367
[20]  
LINDAHL B, 1987, ANTICANCER RES, V7, P781